The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Abdullah Mohammad KhanPublished in: Journal of personalized medicine (2022)
Waldenström's macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BTKi). The focus of this review is to highlight the role of BTKi in the management of WM. The first BTKi to receive US Food and Drug Administration approval for WM was ibrutinib. Ibrutinib has been extensively studied in both treatment-naïve WM patients and in those with relapsed/refractory disease. The next BTKi approved for use was zanubrutinib, and prospective data for acalabrutinib and tirabrutinib have also recently been published. Efficacy data for BTKi will be discussed, as well as the differences in their adverse event profiles.
Keyphrases
- drug administration
- small molecule
- electronic health record
- end stage renal disease
- newly diagnosed
- big data
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multidrug resistant
- randomized controlled trial
- emergency department
- multiple myeloma
- patient reported outcomes
- climate change
- risk assessment
- data analysis